SureTrader Nadex Advertisement Interactive Brokers Advertisement SureTrader
Home > Boards > US OTC > Medical - Healthcare >

Oxis International Inc. (OXIS)

OXIS RSS Feed
Add OXIS Price Alert      Hide Sticky   Hide Intro
Moderator: CashBowski, Tagprofenrir
Search This Board: 
Last Post: 5/23/2017 11:13:12 AM - Followers: 163 - Board type: Free - Posts Today: 5


 

Oxis International Inc.

Below shows OXS-1550 WORKING - Soon to enter Phase II with FDA!

Overview

Treating Non-Hodgkin's lymphoma

OXS-1550 targets cancer cells expressing the CD19 receptor or CD22 receptor or both receptors. When OXS-1550 binds to cancer cells, the cancer cells internalize OXS-1550 and are killed due to the action of drug's cytotoxic payload. OXS-1550 has demonstrated success in early human clinical trials in patients with relapsed/refractory B-cell lymphoma or leukemia.

Treating triple-negative breast cancer

Our lead drug candidate, OXS-2175, is a small molecule therapeutic candidate targeting the treatment of triple-negative breast cancer. In in vitro and in vivo models of TNBC, OXS-2175 demonstrated the ability to inhibit metastasis.

Treating multiple myeloma

Our lead drug candidate, OXS-4235, also a small molecule therapeutic candidate, targets the treatment of multiple myeloma and associated osteolytic lesions. In in vitro and in vivo models of multiple myeloma and osteoporosis, OXS-4235 demonstrated the ability to kill multiple myeloma cells, and decrease osteolytic lesions in bone.


Management



 

Company Website
http://oxis.com

 


Corporate Overview - Presentation
Fall 2015
Click the link: http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=10968247


 




 





 

 

OXIS Conference Call  March 31, 2015

CEO Interview with The Wolf of Weedstreet

 

SCIENTIFIC ADVISORY BOARD

XIANG-QUN (SEAN) XIE, M.D., Ph.D., EMBA

Sean Xie, MD, PhD, EMBA is a tenured Professor at the Department of Pharmaceutical Sciences/Drug Discovery Institute at University of Pittsburgh and Associate Dean for Research Innovation at the School of Pharmacy. He is Principal Investigator of an integrated research laboratory of CompuGroup, BioGroup and ChemGroup, and Founding Director of Computational Chemical Genomics Screening Center. Dr. Xie is also Director/PI of NIH funded National Center of Excellence for Computational Drug Abuse Research. Dr. Xie holds joint faculty positions at the Departments of Computational System Biology and Structural Biology, and Pittsburgh Cancer Institute MT/DD Program. He serves as an invited guest editor for AAPS Journal, Editorial Board of American Journal of Molecular Biology, and Associate Editor of BMC Pharmacology and Toxicology. In 2013, he was named an honorary professor of Chinese Academy of Medical Sciences & Peking Union Medical College. Dr. Xie is a recipient of the 2014 American Association of Pharmaceutical Scientists (AAPS) Outstanding Research Achievement Award.

JAMES J. MULE, Ph.D.

Dr. James J. Mule, Ph.D. serves as an Executive Vice President and Associate Center Director for Translational Research, the Michael McGillicuddy Endowed Chair for Melanoma Research and Treatment, and the Co-Director of the Donald A. Adam Comprehensive Melanoma Center at the Moffitt Cancer Center. He then moved to Palo Alto, Calif., where he was involved in the birth of two startup companies while an adjunct faculty member in the Department of Surgery, Stanford University. He moved to Ann Arbor, Mich., as the Director of the Tumor Immunology and Immunotherapy Clinical Research Programat the University of Michigan Comprehensive Cancer Center. Dr. Mule is recognized for his translational research studies in cancer immunotherapy. His research group is involved in vaccine strategies and other approaches to stimulate the immune system to recognize and destroy tumors. The work in these areas has helped to develop new treatments for advanced cancer patients. Dr. Mule serves on the Advisory Boards of seven NCI-designated Cancer Centers and was a member of the NCI’s Board of Scientific and Clinical Counselors. He serves as Chair of the Cellular, Tissue and Gene Therapy Advisory Committee of CBER, FDA, is a Special Government Employee of the NCI and the FDA. Dr. Mule is recognized for his research and clinical contributions to cancer immunotherapy, particularly in solid tumors.

STEPHEN M. CHANG, Ph.D.

Dr. Stephen M. Chang is Vice President-Research & Development at New York Stem Cell Foundation, Chief Scientific Officer at Stemgent, Inc., and Independent Director at MultiCell Technologies, Inc. He is on the Board of Directors at MultiCell Technologies, Inc. Dr. Chang was previously employed as Chief Scientific Officer & Vice President by Canji, Inc., Chief Scientific Officer & Vice President by Schering-Plough Research Institute, and President & Chief Executive Officer by MultiCell Immunotherapeutics, Inc. He also served on the board at Histogen, Inc. He received his undergraduate degree from the University of Michigan and a doctorate degree from the University of California, Irvine.

LISA A. HAILE, Ph.D.

Dr. Haile has special technical experience in molecular biology, immunology, plant biotechnology, including transgenic plants, cell biology, diagnostics, therapeutics, theranostics, virology, drug delivery systems, host-vector systems, high throughput screening and bioinformatics. She has particular experience with patentability, non-infringement and validity opinions; licensing strategies; FDA counseling; due diligence work in connection with venture capital, private and public financing; mergers and acquisitions in the life sciences industry; and strategic counseling for comprehensive life sciences patent portfolio management. Dr. Lisa Haile concentrates on patent protection.

 

Information on Multiple Myeloma & Cannabidiol (CBD)

After studying the effects of cannabidiol on multiple myeloma cells, researchers found that; “CBD by itself or in synergy with BORT strongly inhibited growth, arrested cell cycle progression and induced MM cells death by regulating the ERK, AKT and NF-κB pathways with major effects in TRPV2+ cells.”

They conclude that; “These data provide a rationale for using CBD to increase the activity of proteasome inhibitors in MM.”

The study, which validates a recent National Institute of Health study which also found that cannabidiol can inhibit cancer cells, was conducted by researchers at the School of Pharmacy at the University of Camerino in Italy.

 Chart

Stock Information:


 
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
OXIS
Current Price
Volume:
Bid Ask Day's Range
OXIS News: Information Statement - All Other (definitive) (def 14c) 05/12/2017 04:03:59 PM
OXIS News: Information Statements (revised) (prer14c) 05/05/2017 05:21:15 PM
OXIS News: Quarterly Report (10-q) 04/28/2017 04:23:56 PM
OXIS News: Information Statements (revised) (prer14c) 04/24/2017 05:30:49 PM
OXIS News: Information Statements (revised) (prer14c) 04/14/2017 01:07:47 PM
PostSubject
#9588  Sticky Note The topic of this board is OXIS. The CashBowski 03/31/17 11:03:34 AM
#10514   I've posted what I found. No point in simon wagstaff 05/23/17 11:13:12 AM
#10513   Like I said, we can circle back around mrcraigo 05/23/17 10:03:36 AM
#10512   That's certainly what they want you to believe. simon wagstaff 05/23/17 10:01:24 AM
#10511   Let's just say that I believe there is mrcraigo 05/23/17 09:18:51 AM
#10510   Care to share any specifics? simon wagstaff 05/23/17 08:27:30 AM
#10509   My Due Diligence says you are wrong, but mrcraigo 05/22/17 03:26:05 PM
#10508   Besides the reverse split and massive dilution? simon wagstaff 05/22/17 03:23:42 PM
#10507   I am very much looking forward to the mrcraigo 05/22/17 02:59:08 PM
#10506   Sorry, I believe that you are incorrect. It simon wagstaff 05/22/17 02:02:28 PM
#10505   Bottom line it is all about the science.......... mrcraigo 05/22/17 12:59:47 PM
#10504   Do you mean phase II? Already priced in. simon wagstaff 05/22/17 12:57:02 PM
#10503   If they continue to finance operations with selling CashBowski 05/22/17 11:45:35 AM
#10502   Time will tell..... Willing to bet you are mrcraigo 05/21/17 07:46:56 PM
#10501   agreed Fibanotch 05/18/17 10:29:22 AM
#10500   I figure once the reverse split occurs it scoot27 05/18/17 10:26:03 AM
#10498   Kiss it good bye! Average down? simon wagstaff 05/18/17 07:57:22 AM
#10497   what now? Fibanotch 05/17/17 08:09:55 PM
#10496   R/S on 20th trading day from May 16th Gibba 05/17/17 05:19:52 PM
#10495   Reverse split..... mrcraigo 05/17/17 04:46:46 PM
#10494   R/S ...What now? Fibanotch 05/17/17 10:47:32 AM
#10493   You're right 100# mrcraigo 05/15/17 11:10:10 PM
#10492   First thing after RS, probably same day will jimbosskow 05/12/17 06:36:57 PM
#10491   I don't think they really care about current scoot27 05/12/17 05:08:41 PM
#10490   I still don't think it's a scam but jimbosskow 05/12/17 04:50:38 PM
#10489   no vol, mean nothing. Recall it was dropped chromaticity 05/12/17 02:13:12 PM
#10488   18% gain? OxisWatcher 05/12/17 01:39:07 PM
#10487   One more scam bites the dust. simon wagstaff 05/11/17 07:06:48 PM
#10486   Sad... jimbosskow 05/11/17 06:25:54 PM
#10485   Yes, a lot of shares, anywhere from 50-300 Gibba 05/10/17 12:25:28 PM
#10484   Will current stockholder's shares be fractionalized after the R/S? Rocketcar7 05/10/17 07:02:35 AM
#10483   Agree - this well is empty. Gibba 05/09/17 07:08:39 PM
#10482   Even a Pump & Dumper realizes the well scoot27 05/09/17 03:26:04 PM
#10481   Gee, a few weeks ago you would have simon wagstaff 05/09/17 01:18:36 PM
#10480   I am not convinced that any trial results simon wagstaff 05/08/17 09:12:18 AM
#10479   shes a tricky one, this should be the chico hombre2 05/07/17 02:52:47 PM
#10478   AS increase and RS. Cya in a Cheds 05/06/17 09:04:44 PM
#10477   too bad to stay on the earth. to chromaticity 05/02/17 05:10:53 PM
#10476   This will likely be deleted. Suspended until 2020. simon wagstaff 05/01/17 11:32:05 PM
#10474   They cured a ladies cancer! simon wagstaff 05/01/17 02:02:20 PM
#10473   Any day now, Because CEO said they will munimi 05/01/17 10:49:32 AM
#10472   Any date for the R/S? Thanks Soup Stock 05/01/17 10:44:05 AM
#10471   No glitch. Sec done with pumps. Sonicimpulse1 04/30/17 12:11:20 AM
#10470   Dont touch this, it is a reverse split munimi 04/28/17 10:36:17 PM
#10469   6000 ticketsymbols were halted today, there was a Box Money 04/28/17 05:25:34 PM
#10468   10Q out, dilution monster whoooooah sweet assets.... NOT chico hombre2 04/28/17 04:32:09 PM
#10467   The RS isn't listed on Finra daily list, CashBowski 04/28/17 01:25:57 PM
#10466   There's currently 360 OTC tickers in a U3 CashBowski 04/28/17 11:19:25 AM
#10465   Thank you! Mbrew34 04/28/17 11:18:24 AM
#10464   R/S occuring JayP-Diddy 04/28/17 11:16:50 AM
#10463   Oxis halted? Mbrew34 04/28/17 10:40:20 AM
PostSubject